胸腺肽治疗慢性心力衰竭的临床疗效观察  

Immunomodulating Therapy with Intravenous Thymopetidum in Patients with Chronic Heart Failure

作　　者：彭雯[1] 张秀娥[1] 张湖萍[1] 

机构地区：[1]华中科技大学同济医学院协和医院老年病科,湖北武汉430022

出　　处：《医学临床研究》2006年第9期1364-1365,1369,共3页Journal of Clinical Research

摘　　要：【目的】探讨静脉注射胸腺肽对慢性心力衰竭(CHF)患者炎性反应及其心功能的影响。【方法】46例CHF患者随机分为两组:安慰剂组和胸腺肽组,疗程3个月。【结果】①胸腺肽组可以显著增加白介素-10(IL-10)、白介素-1受体抑制物(IL-1Ra)的血浆水平;②胸腺肽组可以增加CHF患者的射血分数和6 min步行距离(6-MWT)。【结论】胸腺肽可以减轻CHF患者的炎性反应,改善心功能,提示除了传统的CHF治疗方案以外,免疫调节治疗可以起到积极的作用。Objective To study the effect of immunomodulating therapy with intravenous thymopetidum in patients with chronic heart failure（CHF）. [Methods]Fourty six CHF patients were randomly divided into two groups ： thymopetidum group received therapy with Thymopetidum for 3 months, another group was control group, [Results]Changes were observed in patients after 3 months of thymopetidum therapy： （DThymopetidum, but not control, induced a marked rise in plasma levels of the anti-inflammatory mediators interleukin-10 （IL-10） ,IL-1 receptor antagonist（.IL-1Ra） ; ② induced a significant increase in the maximum distance walk and EF. [Conclusion]Thymopetidum-induced change favors an anti-inflammatory effect in CHF. This effect is significantly correlated with an improvement in LVEF, suggesting a potential immunomodulating therapy in addition to optimal conventional cardiovascular treatment regimens in CHF patients.

关 键 词：心力衰竭 充血性/药物疗法 胸腺素/治疗应用 

分 类 号：R541.61[医药卫生—心血管疾病]